Abstract
Mutations of fms-like tyrosine kinase 3 (FLT3) and nucleophosmin (NPM1) exon 12 genes are the most common abnormalities in adult acute myeloid leukemia (AML) with normal cytogenetics. To assess the prognostic impact of the two gene mutations in Chinese AML patients, we used multiplex polymerase chain reaction (PCR) and capillary electrophoresis to screen 76 AML patients with normal cytogenetics for mutations in FLT3 internal tandem duplication (FLT3/ITD) and exon 12 of the NPM1 gene. FLT3/ITD mutation was detected in 15 (19.7%) of 76 subjects, and NPM1 mutation in 20 (26.3%) subjects. Seven (9.2%) cases were positive for both FLT3/ITD and NPM1 mutations. Significantly more FLT3/ITD aberration was detected in subjects with French-American-British (FAB) M1 (42.8%). NPM1 mutation was frequently detected in subjects with M5 (47.1%) and infrequently in subjects with M2 (11.1%). FLT3 and NPM1 mutations were significantly associated with a higher white blood cell count in peripheral blood and a lower CD34 antigen expression, but not age, sex, or platelet count. Statistical analysis revealed that the FLT3/ITDpositive group had a lower complete remission (CR) rate (53.3% vs. 83.6%). Survival analysis showed that the FLT3/ITD-positive/NPM1 mutation-negative group had worse overall survival (OS) and relapse-free survival (RFS). The FLT3/ITD-positive/NPM1 mutation-positive group showed a trend towards favorable survival compared with the FLT3/ITD-positive/NPM1 mutation-negative group (P=0.069). Our results indicate that the FLT3/ITD mutation might be a prognostic factor for an unfavorable outcome in Chinese AML subjects with normal cytogenetics, while NPM1 mutation may be a favorable prognostic factor for OS and RFS in the presence of FLT3/ITD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baarcenai, A., Muench, M.O., Roncarolo, M.G., Spits, H., 1995. Tracing the expression of CD7 and other antigens during T- and myeloid-cell differentiation in the human fetal liver and thymus. Leuk. Lymphoma, 17(1):1–11. [dio:10.3109/10428199509051697]
Baldus, C.D., Thiede, C., Soucek, S., Bloomfield, C.D., Thiel, E., Ehninger, G., 2006. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J. Clin. Oncol., 24(5):790–797. [dio:10.1200/JCO.2005.01.6253]
Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R., Sultan, C., 1985. Proposed revised criteria of the classification of acute myeloid leukemia. Ann. Intern. Med., 103(4):620–625.
Colovic, N., Tosic, N., Aveic, S., Djuric, M., Milic, N., Bumbasirevic, V., Colovic, M., Pavlovic, S., 2007. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia. Ann. Hematol., 86(10):741–747. [dio:10.1007/s00277-007-0325-3]
Döhner, K., Schlenk, R.F., Habdank, M., Scholl, C., Rücker, F.G., Corbacioglu, A., Bullinger, L., Fröhling, S., Döhner, H., 2005. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood, 106(12):3740–3746. [dio:10.1182/blood-2005-05-2164]
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al., 2005. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N. Engl. J. Med., 352(3):254–266. [dio:10.1056/NEJMoa041974]
Fröhling, S., Schlenk, R.F., Breitruck, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H., Döhner, K., 2002. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood, 100(13):4372–4380. [dio:10. 1182/blood-2002-05-1440]
Grundler, R., Miething, C., Thiede, C., Peschel, C., Duyster, J., 2005. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood, 105(12):4792–4799. [dio:10.1182/blood-2004-11-4430]
Hayakawa, F., Towatari, M., Kiyoi, H., Tanimoto, M., Kitamura, T., Saito, H., Naoe, T., 2000. Tandem-duplicated FLT3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene, 19(5):624–631. [dio:10.1038/sj.onc.1203354]
Huang, Q., Chen, W., Gaal, K.K., Slovak, M.L., Stein, A., Weiss, L.M., 2008. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics. Br. J. Haematol., 142(3): 489–492. [dio:10.1111/j.1365-2141.2008.07205.x]
Kelly, L.M., Liu, Q., Kutok, J.L., Williams, I.R., Boulton, C.L., Gilliland, D.G., 2002. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood, 99(1):310–318. [dio:10.1182/blood.V99.1.310]
Kiyoi, H., Ohno, R., Ueda, R., Saito, H., Naoe, T., 2002. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene, 21(16):2555–2563. [dio:10.1038/sj.onc.1205332]
Mori, Y., Yoshimoto, G., Kumano, T., Miyamoto, T., Iino, T., Takenaka, K., Iwasaki, H., Harada, N., Kinukawa, N., Nagafuji, K., 2007. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation. Eur. J. Haematol., 79(1):17–24. [dio:10.1111/j.1600-0609.2007.00866.x]
Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., Misawa, S., 1996. Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia, 10(12):1911–1918.
Pabst, T., Mueller, B.U., Zhang, P., Radomska, H.S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., Tenen, D.G., 2001. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPα), in acute myeloid leukemia. Nat. Genet., 27(3): 263–270. [dio:10.1038/85820]
Rabinowich, H., Pricop, L., Herberman, R.B., Whiteside, T.L., 1994. Expression and function of CD7 molecule on human natural killer cells. J. Immunol., 152(2):517–526.
Rausei-Mills, V., Chang, K.L., Gaal, K.K., Weiss, L.M., Huang, Q., 2008. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3-ITD mutation. Am. J. Clin. Pathol., 129(4):624–629. [dio:10.1309/NRTX9AKXHR5JBT93]
Rocnik, J.L., Okabe, R., Yu, J.C., Lee, B.H., Giese, N., Schenkein, D.P., Gililand, D.G., 2006. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood, 108(4):1339–1345. [dio:10.1182/blood-2005-11-011429]
Schichman, S.A., Caligiuri, M.A., Strout, M.P., Carter, S.L., Gu, Y., Canaani, E., Bloomfield, C.D., Croce, C.M., 1994. ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. Cancer Res., 54:4277–4280.
Schlenk, R.F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., 2008. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med., 358(18):1909–1918. [dio:10.1056/NEJMoa074306]
Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., Löffler, H., Sauerland, C.M., Serve, H., Büchner, T., 2002. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100(1):59–66. [dio:10.1182/blood.V100.1.59]
Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C., Martelli, M.F., Haferlach, T., Hiddemann, W., Falini, B., 2005. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106(12):3733–3739. [dio:10.1182/blood-2005-06-2248]
Suzuki, T., Kiyoi, H., Ozeki, K., Tomita, A., Yamaji, S., Suzuki, R., Kodera, Y., Miyawaki, S., Asou, N., Kuriyama, K., 2005. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood, 106(8):2854–2861. [dio:10.1182/blood-2005-04-1733]
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., 2002. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99(12):4326–4335. [dio:10.1182/blood.V99.12.4326]
Thiede, C., Koch, S., Creutzig, E., Steudel, C., Illmer, T., Schaich, M., Ehninger, G., 2006. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood, 107(10): 4011–4020. [dio:10.1182/blood-2005-08-3167]
Tse, K.F., Allebach, J., Levis, M., Smith, B.D., Bohmer, F.D., Small, D., 2002. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia, 16(10): 2027–2036. [dio:10.1038/sj.leu.2402674]
Verhaak, R.G., Goudswaard, C.S., van Putten, W., Bijl, M.A., Sanders, M.A., Hugens, W., Uitterlinden, A.G., Erpelinck, CA., Delwel, R., Löwenberg, B., 2005. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood, 106(12):3747–3754. [dio:10.1182/blood-2005-05-2168]
Yanada, M., Matsuo, K., Suzuki, T., Kiyoi, H., Naoe, T., 2005. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia, 19(8): 1345–1349. [dio:10.1038/sj.leu.2403838]
Zheng, R., Friedman, A.D., Small, D., 2002. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations. Blood, 100(12):4154–4161. [dio:10.1182/blood-2002-03-0936]
Zheng, R., Friedman, A.D., Levis, M., Li, L., Weir, E.G., Small, D., 2004. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression. Blood, 103(5):1883–1890. [dio:10.1182/blood-2003-06-1978]
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, L., Xu, Wl., Meng, Ht. et al. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics. J. Zhejiang Univ. Sci. B 11, 762–770 (2010). https://doi.org/10.1631/jzus.B1000052
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B1000052
Key words
- Acute myeloid leukemia (AML)
- Normal cytogenetics
- Prognosis
- fms-like tyrosine kinase 3 internal tandem duplication (FLT3/ITD)
- Nucleophosmin (NPM1)
- Mutation